Weight Loss
SEMAGLUTIDE
SIDE EFFECTS
What the clinical data actually shows, which side effects are common vs. rare, and how to manage them. An honest guide for anyone considering or starting GLP-1 therapy.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated April 2026
Book Weight Loss Consultation
Quick answer: GI side effects (nausea, constipation, diarrhea) are the most common. They're dose-dependent, worst in the first 2-4 weeks, and improve significantly as your body adjusts. Most people tolerate GLP-1 medications well with proper dose titration. Serious side effects are rare. The side effects of untreated obesity are far more dangerous than the side effects of the medications used to treat it.
MOST COMMON SIDE EFFECTS
The most common semaglutide side effects are gastrointestinal. In the STEP clinical trials (semaglutide 2.4mg for weight management), GI side effects were reported by 30-50% of participants. The good news: they're almost always mild to moderate, dose-dependent, and transient.
These side effects are a direct consequence of how GLP-1 receptor agonists work. Semaglutide slows gastric emptying, reduces appetite signaling, and changes how your gut processes food. Your body needs time to adapt.
Nausea (30-45%)
The single most reported side effect. Typically worst during weeks 1-4 and after each dose increase. In the STEP 1 trial, 44% of semaglutide patients reported nausea vs. 17% on placebo. Most cases were mild to moderate. Only 4.5% of patients discontinued due to GI events overall.
Constipation or Diarrhea (15-30%)
Semaglutide slows gastric emptying, which can cause constipation in some patients and diarrhea in others. Both are dose-dependent and usually improve over time. Adequate hydration and fiber intake help significantly. Constipation was reported in 24% of patients in STEP 1.
Vomiting (10-25%)
Less common than nausea and usually occurs with dose increases or overeating while on therapy. GLP-1s reduce your appetite and stomach capacity — eating a pre-treatment portion size is a common trigger. Learning to eat smaller meals resolves this for most people.
Abdominal Pain / Bloating (10-20%)
Mild abdominal discomfort and bloating are related to slower gastric emptying. Food stays in your stomach longer, which can feel unfamiliar. This typically resolves within the first few weeks as your eating patterns adjust to match your new satiety signals.
Decreased Appetite
This is the mechanism, not really a side effect. GLP-1 receptor agonists work by reducing appetite and increasing satiety. The challenge isn't that your appetite decreases — it's making sure you still eat enough protein and nutrients despite reduced hunger. A structured nutrition plan prevents this from becoming a problem.
Why Slow Titration Matters
GI side effects are directly linked to how quickly the dose is increased. This is why Moonshot starts at the lowest effective dose and increases gradually over weeks. Patients who jump to high doses or get medication without proper titration protocols are far more likely to have significant nausea and GI distress.
Context that matters: In the STEP 1 trial, only 7% of patients on semaglutide 2.4mg discontinued due to adverse events (vs. 3.1% on placebo). That means 93% of patients tolerated the medication well enough to continue treatment through a 68-week trial. Most GI side effects are front-loaded — they're worst early and improve with time.
LESS COMMON SIDE EFFECTS (5-15%)
These side effects occur in a smaller percentage of patients and are generally mild and transient. Most resolve on their own without dose adjustment.
Headache (10-14%): Reported in clinical trials at rates slightly above placebo. Usually occurs in the first 1-2 weeks and is often related to reduced caloric intake or dehydration rather than the medication itself. Staying hydrated and maintaining adequate nutrition typically resolves this.
Fatigue (5-11%): Transient fatigue is common in the first 1-2 weeks as your body adjusts to lower caloric intake and metabolic changes. It almost always resolves without intervention. If fatigue persists, your provider should check for nutritional deficiencies or inadequate protein intake.
Dizziness (5-7%): Occasional dizziness may occur, particularly when transitioning to lower caloric intake. If you've been eating 3,000 calories and your appetite drops to 1,500, your body needs time to adjust. Adequate hydration and not skipping meals help.
Injection site reactions (5-10%): Redness, itching, or mild swelling at the injection site. Rotating injection sites (abdomen, thigh, upper arm) minimizes this. These reactions are cosmetic and temporary — not a sign of allergy or intolerance.
Acid reflux / GERD (5-10%): Slower gastric emptying can worsen existing reflux or trigger new symptoms. Eating smaller meals, avoiding lying down after eating, and reducing fatty and spicy foods usually manage this. In some cases, dose adjustment is needed.
Hair thinning (telogen effluvium): This is related to rapid weight loss, not the drug itself. It happens with bariatric surgery, crash diets, and any method of significant caloric restriction. Adequate protein intake (0.8-1g per pound of target body weight), proper nutrition, and gradual weight loss help prevent it. Hair thinning from weight loss is temporary and typically regrows within 6-12 months.
RARE / SERIOUS SIDE EFFECTS (<1-2%)
These side effects are uncommon but important to understand. Medical supervision exists specifically to monitor for and catch these early.
Pancreatitis (<1%)
Rare but serious. In the STEP trials, pancreatitis occurred in <0.2% of semaglutide patients. Symptoms include severe, persistent abdominal pain radiating to the back, often with nausea and vomiting. If you experience sudden, severe abdominal pain, contact your provider immediately. Patients with a history of pancreatitis should discuss this risk before starting GLP-1 therapy.
Gallbladder Problems (1-2%)
Gallstones (cholelithiasis) are more common with rapid weight loss from any method — bariatric surgery carries the same risk. In the STEP 1 trial, cholelithiasis-related events occurred in 1.6% of semaglutide patients vs. 0.7% on placebo. Symptoms include right-upper-quadrant abdominal pain, especially after fatty meals. Your provider monitors for this with regular check-ins and symptom assessment.
Thyroid C-Cell Tumors (FDA Black Box Warning)
Semaglutide carries an FDA black box warning based on thyroid C-cell tumor findings in rodent studies at doses 2-10x higher than human doses. No confirmed human cases have been attributed to semaglutide. This warning applies to all GLP-1 receptor agonists as a class. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Thyroid function is monitored in our standard lab panels.
Hypoglycemia (Rare in Non-Diabetics)
Semaglutide lowers blood sugar in a glucose-dependent manner, meaning it primarily acts when blood sugar is elevated. Significant hypoglycemia is rare in patients not taking insulin or sulfonylureas. In the STEP trials (non-diabetic patients), clinically significant hypoglycemia was uncommon. Patients on diabetes medications should have their doses adjusted when starting GLP-1 therapy.
Kidney Injury (Rare)
Severe GI side effects (vomiting, diarrhea) can cause dehydration, which in rare cases can lead to acute kidney injury — particularly in patients with pre-existing kidney disease. This is preventable with adequate hydration and prompt treatment of severe GI symptoms. Kidney function is included in standard monitoring labs.
Perspective: Semaglutide has been prescribed to millions of patients since 2017. The SELECT cardiovascular outcomes trial (17,600+ patients, 3+ years follow-up) showed semaglutide reduced major adverse cardiovascular events by 20%. For most patients, the cardiovascular benefits and metabolic improvements significantly outweigh the risk profile. The key is proper patient selection and ongoing medical supervision.
CONSIDERING GLP-1 THERAPY?
We monitor labs, DEXA body composition, and adjust dosing to minimize side effects. Supervised weight loss in Park Ridge, IL.
SEMAGLUTIDE VS TIRZEPATIDE SIDE EFFECTS
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist, while semaglutide (Ozempic/Wegovy) targets only GLP-1 receptors. The addition of GIP receptor activation gives tirzepatide a slightly different side effect profile, though the overall GI side effect rates are comparable.
| Side Effect | Semaglutide (STEP Trials) | Tirzepatide (SURMOUNT Trials) |
|---|---|---|
| Nausea | 44% | 24-33% |
| Diarrhea | 30% | 18-23% |
| Vomiting | 24% | 8-13% |
| Constipation | 24% | 14-17% |
| Discontinuation (GI) | 4.5% | 4.3-7.1% |
| Avg Weight Loss | ~15-17% body weight | ~18-22.5% body weight |
Key Differences
Tirzepatide tends to produce slightly lower rates of nausea and vomiting compared to semaglutide at equivalent efficacy levels. The GIP receptor activation may provide some GI-protective effects. However, tirzepatide's higher-dose ranges (10mg, 15mg) can still produce significant GI side effects. Neither drug has a clear "winner" on tolerability — individual response varies. Some patients tolerate one better than the other.
Same Principles Apply
Both medications require slow dose titration, both have GI side effects that improve over time, and both benefit from the same management strategies: smaller meals, adequate hydration, avoiding high-fat foods, and medical supervision. The choice between them depends on individual response, insurance coverage, availability, and provider recommendation. Read our full semaglutide vs tirzepatide comparison for more detail.
THE MUSCLE LOSS CONCERN
This is one of the most discussed topics around GLP-1 medications. The concern is legitimate, but widely misunderstood. Weight loss from any method — GLP-1 medications, caloric restriction, bariatric surgery, even diet and exercise alone — includes some lean mass loss. This is basic physiology, not a drug side effect.
In the STEP trials, approximately 25-40% of total weight lost was lean mass. This ratio is consistent with what's seen in bariatric surgery studies and significant caloric restriction. The question isn't whether lean mass loss occurs — it's whether you take steps to minimize it.
Protein Intake
Target 0.8-1g of protein per pound of target body weight. This is the single most important factor in preserving muscle during weight loss. GLP-1 medications reduce appetite, which means you need to be intentional about prioritizing protein at every meal. Low protein intake accelerates lean mass loss. High protein intake preserves it.
Resistance Training
Lifting weights or doing bodyweight resistance exercises 2-4x per week is the second most important factor. Mechanical loading signals your body to preserve and build muscle tissue even during a caloric deficit. Cardio-only exercise programs during GLP-1 therapy are a missed opportunity for muscle preservation.
DEXA Monitoring
A scale can't tell you whether you're losing fat or muscle. A DEXA scan can. By tracking lean mass and fat mass separately, you and your provider can adjust your nutrition and training protocol if muscle loss is disproportionate. This is why Moonshot includes DEXA scans in the weight loss program.
The Real Risk
The muscle loss problem is not inherent to GLP-1 medications. It's a consequence of unsupervised use — patients who get semaglutide without nutrition guidance, don't track protein, skip resistance training, and never measure body composition. Under proper medical supervision with a structured program, lean mass preservation is manageable and measurable.
Bottom line: Muscle loss during GLP-1 therapy is not inevitable — it's manageable. The combination of adequate protein, resistance training, and DEXA-based body composition monitoring converts this from a scary headline into a trackable, solvable variable. This is the difference between supervised and unsupervised weight loss.
HOW TO MANAGE GLP-1 SIDE EFFECTS
Most GLP-1 side effects are manageable with simple behavior changes. These strategies come from clinical experience managing hundreds of patients through dose titration.
Eat Smaller Meals
GLP-1 medications slow gastric emptying. Your stomach capacity is effectively reduced. Eating pre-treatment portion sizes is the most common cause of nausea and vomiting. Shift to 4-5 smaller meals rather than 2-3 large ones. Stop eating when you feel satisfied, not full.
Avoid High-Fat Foods
Fatty foods already slow gastric emptying. Combined with a GLP-1 medication, high-fat meals can sit in your stomach for hours and trigger nausea. Prioritize lean proteins, vegetables, and complex carbohydrates — especially in the first few weeks and after dose increases.
Stay Hydrated
Dehydration worsens nausea, headache, constipation, and fatigue. Aim for 64-100oz of water daily. Sip water throughout the day rather than drinking large amounts at once. If you're experiencing diarrhea or vomiting, replace electrolytes as well.
Start Low, Go Slow
Dose titration is the single biggest lever for managing side effects. Starting at the lowest dose and increasing every 4 weeks (or longer if needed) gives your body time to adjust. Patients who skip titration steps or escalate too quickly have significantly worse GI symptoms.
Manage Constipation
Increase fiber intake (fruits, vegetables, psyllium husk), stay hydrated, and maintain physical activity. If constipation persists, your provider may recommend a stool softener or fiber supplement. Don't ignore it — chronic constipation affects quality of life and medication adherence.
Talk to Your Provider
If side effects are persistent or affecting your daily life, don't power through. Dose adjustment, temporary dose reduction, or switching medications are all viable options. The goal is finding the lowest effective dose that produces weight loss with tolerable side effects. Your provider has tools to help — use them.
WHAT MOONSHOT MONITORS
The difference between supervised and unsupervised GLP-1 use is monitoring. Telehealth mills that prescribe semaglutide without labs, body composition tracking, or regular follow-ups are leaving patients exposed to preventable risks.
Comprehensive Lab Work
Baseline and ongoing labs including thyroid function (TSH, free T3/T4), liver enzymes (ALT, AST), kidney function (BUN, creatinine, GFR), fasting glucose and HbA1c, lipid panel, and inflammatory markers. These catch potential issues before they become problems.
DEXA Body Composition
Periodic DEXA scans track lean mass vs. fat mass changes. This is how we ensure you're losing fat, not muscle. If lean mass loss is disproportionate, we adjust your nutrition and training protocol. A scale alone cannot provide this information.
Dose Titration
Structured dose escalation with check-ins at each step. We don't auto-escalate on a fixed schedule — dose increases are based on your response, tolerability, and weight loss trajectory. Some patients do well at lower doses and don't need to reach the maximum.
Regular Provider Check-Ins
Ongoing follow-ups to assess side effects, adjust dosing, review labs, discuss nutrition and exercise, and make sure the program is working. This is where side effects get caught and managed early, before they become reasons to quit.
Why this matters: Getting semaglutide is easy. Getting semaglutide with proper medical oversight is what separates weight loss that works long-term from weight loss that results in muscle wasting, nutritional deficiencies, and regain. Monitoring isn't overhead — it's the product.
Want supervised GLP-1 therapy with full lab monitoring and DEXA tracking?
Book Weight Loss Consultation or call 224-435-4280SIDE EFFECTS OF NOT TREATING OBESITY
Every medication has side effects. But so does untreated disease. When evaluating whether GLP-1 side effects are "worth it," they need to be weighed against the well-documented, progressive health consequences of obesity.
Cardiovascular Disease
Obesity increases risk of heart attack, stroke, heart failure, and hypertension. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in overweight/obese patients. GLP-1 therapy isn't just cosmetic — it has direct cardiovascular benefit.
Type 2 Diabetes
Obesity is the single largest modifiable risk factor for type 2 diabetes. Every 5kg of weight loss reduces diabetes risk by approximately 50%. GLP-1 medications directly improve insulin sensitivity and glycemic control, preventing or delaying diabetes onset in pre-diabetic patients.
Sleep Apnea
Obstructive sleep apnea affects approximately 45% of obese adults. It causes chronic sleep disruption, daytime fatigue, cardiovascular strain, and cognitive impairment. Weight loss of 10-15% can significantly improve or resolve sleep apnea in many patients.
Joint Damage
Every pound of body weight creates approximately 4 pounds of force on the knee joint during walking. Obesity accelerates osteoarthritis, limits mobility, and increases the likelihood of joint replacement surgery. Weight loss directly reduces joint stress and pain.
Fatty Liver Disease (NAFLD/NASH)
Non-alcoholic fatty liver disease affects up to 75% of obese individuals and can progress to cirrhosis and liver failure. Weight loss of 7-10% has been shown to resolve NASH (the inflammatory form) in a significant percentage of patients. GLP-1 medications are being actively studied for liver-protective effects.
Cancer Risk
Obesity is associated with increased risk of at least 13 types of cancer, including breast, colon, endometrial, kidney, and pancreatic cancer. The mechanisms include chronic inflammation, elevated insulin levels, and hormonal disruption. Weight loss reduces these risk factors.
The real comparison: Temporary nausea and GI discomfort that resolves with dose titration vs. progressive cardiovascular disease, diabetes, joint destruction, liver damage, and increased cancer risk. When you frame GLP-1 side effects against the side effects of the disease they're treating, the risk-benefit calculation is clear for most patients with clinical obesity.
GLP-1 SIDE EFFECTS FAQ
What are the most common semaglutide side effects?
The most common semaglutide side effects are gastrointestinal: nausea (affecting 30-45% of patients in clinical trials), constipation, diarrhea, and decreased appetite. These are dose-dependent and typically worst during the first 2-4 weeks and after dose increases. Most patients find GI side effects improve significantly as their body adjusts, especially with slow dose titration.
How long do GLP-1 side effects last?
Most GLP-1 side effects are transient. Nausea typically peaks in the first 1-4 weeks and after each dose increase, then subsides. Fatigue and headache usually resolve within the first 1-2 weeks. With proper dose titration — starting low and increasing gradually — the majority of patients report side effects becoming mild or absent by weeks 4-8. Persistent symptoms beyond 8 weeks at a stable dose should be discussed with your provider for dose adjustment.
Does semaglutide cause hair loss?
Semaglutide itself does not directly cause hair loss. Hair thinning reported by some patients is a well-known consequence of rapid or significant weight loss (telogen effluvium), regardless of how the weight is lost — it occurs with bariatric surgery, crash diets, and caloric restriction too. Adequate protein intake (0.8-1g per pound of target body weight), proper nutrition, and gradual weight loss help minimize this. Hair thinning from weight loss is temporary and typically resolves within 6-12 months.
Is semaglutide safe long-term?
Semaglutide has been studied in clinical trials lasting up to 2+ years (STEP and SUSTAIN programs) and has been prescribed since 2017 (Ozempic) and 2021 (Wegovy). Long-term data shows sustained efficacy and a consistent safety profile. The SELECT cardiovascular outcomes trial (17,600+ patients, 3+ years follow-up) demonstrated a 20% reduction in major cardiovascular events in patients taking semaglutide. As with any medication, long-term use should include regular monitoring — labs, body composition tracking, and provider check-ins.
Does semaglutide cause muscle loss?
Weight loss from any method — GLP-1 medications, caloric restriction, bariatric surgery — includes some lean mass loss. In the STEP trials, approximately 25-40% of weight lost was lean mass. This is not unique to semaglutide. The solution is resistance training and adequate protein intake (0.8-1g per pound of target body weight). DEXA scans can track body composition changes to ensure muscle is being preserved. At Moonshot Medical, we include DEXA monitoring in our weight loss program specifically for this reason.
What's the difference between Ozempic and Wegovy side effects?
Ozempic and Wegovy contain the same active ingredient (semaglutide) made by the same manufacturer (Novo Nordisk). The side effect profile is essentially identical. The main difference is dosing: Ozempic maxes out at 2.0mg/week (FDA-approved for type 2 diabetes), while Wegovy goes up to 2.4mg/week (FDA-approved for weight management). Higher doses may mean slightly more GI side effects, but the types of side effects are the same. Read our semaglutide cost guide for pricing details.
READY TO START?
Book a weight loss consultation to find out if GLP-1 therapy is right for you. Labs, DEXA monitoring, and ongoing medical supervision included.
Book Weight Loss ConsultationPrefer to talk first? Call 224-435-4280
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results and side effects vary. The clinical trial data cited (STEP, SURMOUNT, SELECT) represents population-level findings — your experience may differ. Always consult a qualified healthcare provider before starting or changing any medication. No provider-patient relationship is established by viewing this content.